Men taking testosterone-blocking drugs to treat prostate cancer have nearly twice the risk of developing Alzheimer’s disease as those using other treatments, according to an analysis of electronic medical records published Monday.

Androgen-deprivation therapy—also known as chemical castration—lowers levels of testosterone and other male hormones that can fuel the growth of prostate cancer. However, it has been linked to a higher risk of cardiovascular disease, diabetes, high cholesterol, impotence, loss of muscle mass,...